Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates

Core Insights - Capricor Therapeutics reported a quarterly loss of $0.16 per share, which was better than the Zacks Consensus Estimate of a loss of $0.31, representing an earnings surprise of 48.39% [1] - The company posted revenues of $11.13 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 248.28%, although this was a decrease from $12.09 million in the same quarter last year [2] - Capricor shares have declined approximately 15.9% year-to-date, compared to a 4.5% decline in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.21 on revenues of $8.25 million, and for the current fiscal year, it is -$0.70 on revenues of $20.78 million [7] - The estimate revisions trend for Capricor is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Products industry, to which Capricor belongs, is currently ranked in the bottom 44% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Another company in the same industry, MacroGenics, is expected to report a quarterly loss of $0.23 per share, with revenues projected to be $45.26 million, reflecting a significant year-over-year increase of 322.2% [9][10]